MENADNA, a leading bioinformatics and genetic testing startup focused in the Middle East and North Africa (MENA) region, has announced a new commercial partnership with Nebula Genomics, a trailblazer in personalized genome sequencing. The high-level collaboration sees MENADNA added as an exclusive partner of Nebula Genomics in Jordan, Oman, and Iraq, with plans already in place for further expansion into Saudi Arabia in the near future.

The partnership will cover an extra 56 million people across the region, and by leveraging the advanced sequencing technologies of Nebula Genomics, MENADNA hopes to expand and upgrade its proprietary bioinformatics platform for what has historically been an underserved region.

The MENA represents a very diverse genetic landscape but is currently underrepresented in global genome-wide association studies (GWAS), which predominantly feature European ancestries. The collaboration aims to contribute valuable data from the region’s population, enriching global genetic databases and advancing local research.

Dr. Bassam El Fahmawi, CEO of MENADNA, shared his vision and enthusiasm for the partnership: “Our collaboration with Nebula Genomics is a game-changer for genomic testing in Jordan, Oman, and Iraq. By combining Nebula’s state-of-the-art sequencing technology with our specialized bioinformatics pipeline, we can provide more accurate, region-specific genomic insights. This is crucial, as less than 2% of genomic data available today comes from the region despite its rich genetic diversity. Our joint efforts will not only enhance patient care but also significantly contribute to the global understanding of genetic variations and their impact on health”.

Also Read: Dubai Police Reveal New 10-Minute Drug Testing Device

Jason Karkus, President of Nebula Genomics, also commented: “Nebula Genomics, a global pioneer in Whole Genome Sequencing, is pleased to partner with MENADNA, bringing our cutting edge, low-cost technology to Jordan, Oman, and Iraq. This is an exciting partnership, which we believe will lead to a substantial business relationship between our companies. Our combined expertise in Whole Genome Sequencing, proprietary reporting, bioinformatics, and large-scale distribution in the region, make us a perfect match for this strategic partnership”.